stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Operating cash flow
BioNTech SE Sponsored ADR's operating cash flow for fiscal 2025 was $515.9M, up 129.5% from $224.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$277.2M. Over the past ten years it has ranged from −$222.4M (fiscal 2019) to $14.3B (fiscal 2022); the current reading is higher than 67% of that period. BioNTech SE Sponsored ADR ranks 565th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $515.9M | 129.55% |
| FY2024 | $224.8M | (96.13%) |
| FY2023 | $5.8B | (59.36%) |
| FY2022 | $14.3B | 1,259.02% |
| FY2021 | $1.1B | — |
| FY2020 | −$15.4M | — |
| FY2019 | −$222.4M | — |
| FY2018 | −$68.7M | — |
| FY2017 | −$59.0M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | −$144.6M | — |
| Jun 2026 | $15.5M | — |
| Mar 2026 | −$492.7M | — |
| Dec 2025 | $344.7M | (61.32%) |
| 26 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.2B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $955.9M |
| GMAB Genmab A/S Sponsored ADR compare | $891.0M |
| INCY Incyte Corporation compare | $745.0M |
| ASND Ascendis Pharma A/S compare | $404.1M |
| BNTX BioNTech SE Sponsored ADR | −$277.2M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.0M |
| INSM Insmed, Inc. compare | −$595.6M |
| ROIV Roivant Sciences Ltd. compare | −$816.5M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement